Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic Cumin

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
ACS Medicinal Chemistry Letters|July 23, 2014
Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitorsTakeru Ehara, Osamu Irie, Takatoshi Kosaka, et al.
Biochemical and Biophysical Research Communications|August 21, 2003
Structure-based design of aliskiren, a novel orally effective renin inhibitorJeanette M Wood, Jürgen Maibaum, Joseph Rahuel, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2014
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactionsAnna Sala-Cunill, Jenny Björkqvist, Riccardo Senter, et al.
Journal of Medicinal Chemistry|January 31, 2013
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophoreNils Ostermann, Simon Ruedisser, Claus Ehrhardt, et al.
Journal of Medicinal Chemistry|June 17, 2017
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in VivoEdwige Lorthiois, Karen Anderson, Anna Vulpetti, et al.
Nature Chemical Biology|November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathwayJürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin InhibitorsToshio Kawanami, Rajeshri G Karki, Emma Cody, et al.
Journal of Medicinal Chemistry|April 18, 2019
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement PathwayRajeshri G Karki, James Powers, Nello Mainolfi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2019
Small-molecule factor B inhibitor for the treatment of complement-mediated diseasesAnna Schubart, Karen Anderson, Nello Mainolfi, et al.
Journal of Medicinal Chemistry|February 20, 2020
Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesNello Mainolfi, Takeru Ehara, Rajeshri G Karki, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
ACS Medicinal Chemistry Letters|July 23, 2014
Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitorsTakeru Ehara, Osamu Irie, Takatoshi Kosaka, et al.
Biochemical and Biophysical Research Communications|August 21, 2003
Structure-based design of aliskiren, a novel orally effective renin inhibitorJeanette M Wood, Jürgen Maibaum, Joseph Rahuel, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2014
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactionsAnna Sala-Cunill, Jenny Björkqvist, Riccardo Senter, et al.
Journal of Medicinal Chemistry|January 31, 2013
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophoreNils Ostermann, Simon Ruedisser, Claus Ehrhardt, et al.
Journal of Medicinal Chemistry|June 17, 2017
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in VivoEdwige Lorthiois, Karen Anderson, Anna Vulpetti, et al.
Nature Chemical Biology|November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathwayJürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin InhibitorsToshio Kawanami, Rajeshri G Karki, Emma Cody, et al.
Journal of Medicinal Chemistry|April 18, 2019
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement PathwayRajeshri G Karki, James Powers, Nello Mainolfi, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2019
Small-molecule factor B inhibitor for the treatment of complement-mediated diseasesAnna Schubart, Karen Anderson, Nello Mainolfi, et al.
Journal of Medicinal Chemistry|February 20, 2020
Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated DiseasesNello Mainolfi, Takeru Ehara, Rajeshri G Karki, et al.
Pageof 2